TAK trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TAK achieves its forward estimates and maintains a stable P/E multiple of 0.3x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Takeda Pharmaceutical Company Limited (TAK) has a Wall Street consensus price target of N/A, based on estimates from 6 covering analysts. The company has a market capitalization of $59.84B.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TAK trades at a trailing P/E of 46.6x and forward P/E of 0.3x. Analysts expect EPS to grow +11.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $2706.42, with bear and bull scenarios of $1705.05 and $3565.98 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVONovo Nordisk A/S | $169.5B | $38.17 | $44.67 | +17.0% | Buy | 1.7x | 39 |
 AZNAstraZeneca PLC | $126.6B | $163.33 | $186.67 | +14.3% | Buy | 15.9x | 41 |
 SNYSanofi | $100.0B | $41.66 | $49.50 | +18.8% | Hold | 10.0x | 27 |
 NVSNovartis AG | $271.3B | $142.71 | $153.00 | +7.2% | Hold | 16.2x | 25 |
 GSKGSK plc | $99.6B | $49.71 | $60.00 | +20.7% | Hold | 13.8x | 29 |
 ABBVAbbVie Inc. | $468.7B | $265.30 | $287.08 | +8.2% | Buy | 18.9x | 43 |
 BMYBristol-Myers Squibb Company | $124.9B | $61.15 | $70.00 | +14.5% | Buy | 8.8x | 42 |
 JNJJohnson & Johnson | $648.0B | $269.17 | $286.93 | +6.6% | Buy | 23.4x | 40 |
 MRKMerck & Co., Inc. | $365.8B | $148.11 | $158.12 | +6.8% | Buy | 53.9x | 38 |
 PFEPfizer Inc. | $160.6B | $28.17 | $28.50 | +1.2% | Hold | 9.5x | 39 |
Quick answers to the most common questions about buying TAK stock.
The consensus price target for TAK is $N/A, close to the current price of $18.81 (N/A% implied move). Based on 6 analyst estimates, the stock appears fairly valued near current levels.
TAK has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
With a forward P/E of 0.2983x, TAK trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $N/A for TAK, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $3566 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
TAK is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TAK stock forecast based on 6 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $2706, with bear/bull scenarios of $1705/$3566.
Our quantitative valuation model calculates TAK's fair value at $2706 (base case), with a bear case of $1705 and bull case of $3566. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
TAK trades at a forward P/E ratio of 0.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 46.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
TAK appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TAK analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $1705-$3566 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.